ERBB2 and breast carcinoma: Third, this study developed clinical and genetic models for HER2+ breast cancer patients who received neoadjuvant chemotherapy and trastuzumab, so whether these models could predict pCR for those who received pertuzumab or tyrosine kinase inhibitors deserved further research.